Abstract | BACKGROUND AND AIMS: STUDY DESIGN: RESULTS: The median number of cycles applied was three (range, 1-15). The ifosfamide dosage reached was 4-13 g/m2 per cycle, median 5 g/m2. A complete response was achieved in 1/21 patient (5%), no partial responses were observed, 4/21 patients (20%) had stable disease, and 16/21 (75%) had progressive disease. No difference in response and stable disease rates was observed between responders and non-responders to first-line chemotherapy. No difference in the ifosfamide dose reached was noted between patients receiving second-line chemotherapy directly following first-line therapy and those with a time interval between first- and second-line chemotherapy. The granulocytopenia grade III nadir lasted for a median of one day (range, 1-3) and other toxicities including hematological toxicity were mild and infrequent. CONCLUSIONS: In view of the swift regeneration from grade III granulocytopenia, continuation of the study with granulocytopenia grade IV as a limiting factor for ifosfamide dose escalation seems feasible, with the prospect of better efficacy without excessive toxicity.
|
Authors | N Babović, S Jelić, N Milanović, S Matković |
Journal | Tumori
(Tumori)
1998 Nov-Dec
Vol. 84
Issue 6
Pg. 677-80
ISSN: 0300-8916 [Print] United States |
PMID | 10080676
(Publication Type: Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents, Alkylating
- Ifosfamide
|
Topics |
- Adult
- Agranulocytosis
(chemically induced)
- Antibiotics, Antineoplastic
(therapeutic use)
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects, therapeutic use)
- Drug Administration Schedule
- Female
- Humans
- Ifosfamide
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Recurrence
- Sarcoma
(drug therapy)
- Severity of Illness Index
- Treatment Outcome
|